- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01128907
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
Galactomannan Antigen and Real Time - PCR for Aspergillus DNA Detection in Bronchoalveolar Lavage. Application in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
Invasive Aspergillosis (IA) is a very serious fungal infection. Hematological patients are the most affected group. IA has a very high morbimortality due to its rapid progression and because it is very difficult to be early diagnosed. Diagnosis is used to be done too late or even post-mortem. They are two new methods (techniques) trying to make the diagnosis on an early stage: detection of Galactomannan antigen of Aspergillus species and real - time polymerase chain reaction (PCR) of its DNA in blood. IA in immunocompromised patients is mainly located in lungs, so our hypothesis is that in patients where the investigators suspect IA the investigators should find earlier Galactomannan antigen or real -time PCR of Aspergillus in respiratory samples such as bronchoalveolar lavage (BAL), and its detection could be useful for diagnosis.
Objectives: To detect Galactomannan Antigen and Real Time - PCR for Aspergillus DNA in bronchoalveolar lavage. To validate the routine utility of these tests in BAL as a diagnostic method of IA and investigate if Galactomannan Antigen and Real Time - PCR for Aspergillus DNA in bronchoalveolar lavage can optimize blood test sensibility.
Methods: Prospective study. The investigators will include 200 patients. 100 of them will be hematological patients, neutropenic and at high risk to develop an IA. The other 100 will be patients without risk or no suspicion at all of IA. The investigators will perform a BAL in all patients. And blood detection of Galactomannan Antigen in hematological patients. The investigators will perform a standard microbiological culture of BAL and Galactomannan Antigen in both samples (bronchoalveolar lavage and blood). The investigators also will carry out Real Time - PCR for Aspergillus DNA detection in bronchoalveolar lavage.
Expected results: To detect Galactomannan Antigen and Real Time - PCR for Aspergillus DNA in BAL with more specificity and making earlier diagnosis than in blood. The investigators also expect to implant these techniques in BAL in the routine for IA diagnosis in neutropenic patients.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- hematological neutropenic patients at high risk of IA in which we usually perform a BAL for microbiological study when they present persistent fever and an opportunist infection suspicion.
- patients without hematological illness and without IA suspicion, in which we perform an BAL because of another reason.
Description
Inclusion Criteria:
- 100 BAL in hematological neutropenic patients at high risk of IA, admitted to our hospital, in which we usually perform a BAL for microbiological study when they present persistent fever and an opportunist infection suspicion.
- 100 BAL in patients without hematological illness and without IA suspicion, in which we perform an BAL because of another reason.
Exclusion Criteria:
- Patients without fulfilling inclusion criteria.
- Patients with some contraindication to perform a bronchoscopy.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
1
Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
|
2
Patients without hematological illness and without Invasive Aspergillosis suspicion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Galactomannan antigen and Real Time - PCR for Aspergillus DNA detection in bronchoalveolar lavage.
Time Frame: 3 years
|
Cross-sectional design.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Utility of Galactomannan antigen and Real Time - PCR for Aspergillus DNA in BAL as a diagnostic method of IA.
Time Frame: 3 years
|
Cross-sectional design.
|
3 years
|
Galactomannan Antigen and Real Time- PCR for Aspergillus DNA in bronchoalveolar lavage can optimize blood test sensibility?
Time Frame: 3 years
|
cross-sectional design.
|
3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR03/03/2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Aspergillosis
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownInvasive Aspergillosis | Invasive Candidiasis
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingInvasive Aspergillosis | Invasive CandidiasisChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedPulmonary Invasive AspergillosisNetherlands
-
Melbourne HealthMerck Sharp & Dohme LLCRecruitingFungal Infection | Pharmacokinetics | Invasive Aspergillosis | Prophylaxis | Invasive Candidiases | Posaconazole | Invasive MycosisAustralia
-
Arkansas Children's Hospital Research InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...RecruitingPulmonary Invasive Fungal Infections | Pulmonary Invasive AspergillosisUnited States, Canada
-
Erasmus Medical CenterGilead SciencesCompletedAspergillosis, Invasive PulmonaryNetherlands
-
Astellas Pharma Global Development, Inc.CompletedInvasive Aspergillosis | Invasive MucormycosisUnited States, Belgium, Spain
-
VicalTerminatedInvasive Aspergillosis | Invasive Pulmonary AspergillosisUnited States, Korea, Republic of, Canada, Belgium, France, Germany
-
Imagine InstituteRecruitingInvasive Aspergillosis | Cerebral AspergillosisFrance
-
Astellas Pharma IncWithdrawnAspergillosis/Blood | Aspergillosis/InvasiveUnited States